Allogeneic transplant for older AML patients - who, when and how
The significance of FLT3 mutations in AML
Challenges with measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
Why we need novel strategies for diffuse large B-cell lymphoma
Treatment for older AML patients - when is an allogeneic transplant suitable?